Mirum Pharmaceuticals raises $120m to advance Maralixibat for rare liver diseases
Mirum Pharmaceuticals, a clinical-stage pharmaceutical company, has successfully raised $120 million in a Series A funding round to propel the development of its lead drug, Maralixibat, aimed at treating rare cholestatic liver diseases. The round was spearheaded by New Enterprise Associates (NEA) and saw participation from other notable investors including Deerfield Management, Frazier Healthcare Partners, […]